Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 17, Issue 1, 2005, Pages 3-18

  Chaiworapongsa, Tinnakorn ^a   Romero, Roberto ^a,e   Kim, Yeon Mee ^a   Kim, Gi Jin ^b   Kim, Mi Ran ^a   Espinoza, Jimmy ^a   Bujold, Emmanuel ^a   Gonçalves, Luis ^a   Gomez, Ricardo ^c   Edwin, Samuel ^b   Mazor, Moshe ^d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e WAYNE STATE UNIVERSITY   (United States)

Author keywords

Early onset; Late onset; Longitudinal study; PIGF; Plasma soluble vascular endothelial growth factor 1; Pre eclampsia; VEGF

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; LONGITUDINAL STUDY; PATHOPHYSIOLOGY; PLACENTA DEVELOPMENT; PREECLAMPSIA; PRIORITY JOURNAL;

ADULT; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; LONGITUDINAL STUDIES; OSMOLAR CONCENTRATION; PRE-ECLAMPSIA; PREGNANCY; RETROSPECTIVE STUDIES; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 20244362656     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/14767050400028816     Document Type: Article

References (139)

1. Romero R, Lockwood C, Oyarzun E, et al. Toxemia: new concepts in an old disease. Semin Perinatol 1988;12:302-323.
2. Redman CW, Sargent IL. The pathogenesis of pre-eclampsia. Gynecol Obstet Fertil 2001;29:518-522.
3. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998;179:1359-1375.
4. Roberts JM, Lain KY. Recent Insights into the pathogenesis of pre-eclampsia. Placenta 2002;23:359-372.
5. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-192.
6. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003;69:1-7.
7. Myatt L. Role of placenta in preeclampsia. Endocrine 2002;19:103-111.
8. Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol 2002;187:1416-1423.
9. Norwitz ER, Hsu CD, Repke JT. Acute complications of preeclampsia. Clin Obstet Gynecol 2002;45:308-329.
10. Martin JN, Jr., Rinehart BK, May WL, et al. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999;180:1373-1384.
11. Robertson WB, Brosens I, Dixon G. Maternal uterine vascular lesions in the hypertensive complications of pregnancy. Perspect Nephrol Hypertens 1976;5:115-127.
12. Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991;98:648-655.
13. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99:2152-2164.
14. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997;99:2139-2151.
15. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:5-15.
16. Hunter CA Jr, Howard WF. A pressor substance (hysterotonin) occurring in toxemia. Am J Obstet Gynecol 1960;79:838-846.
17. Zuspan FP. Catecholamines. Their role in pregnancy and the development of pregnancy-induced hypertension. J Reprod Med 1979;23:143-150.
18. Neale D, Demasio K, Illuzi J, et al. Maternal serum of women with pre-eclampsia reduces trophoblast cell viability: evidence for an increased sensitivity to Fas-mediated apoptosis. J Matern Fetal Neonatal Med 2003;13:39-44.
19. Pirani BB, MacGillivray I. The effect of plasma retransfusion on the blood pressure in the puerperium. Am J Obstet Gynecol 1975;121:221-226.
20. Krege JH, Katz VL. A proposed relationship between vasopressinase altered vasopressin and preeclampsia. Med Hypotheses 1990;31:283-287.
21. McKinney ET, Shouri R, Hunt RS, et al. Plasma, urinary, and salivary 8-epi-prostaglandin f2alpha levels in normotensive and preeclamptic pregnancies. Am J Obstet Gynecol 2000;183:8740-877.
22. Pedersen EB, Aalkjaer C, Christensen NJ, et al. Renin, angiotensin II, aldosterone, catecholamines, prostaglandins and vasopressin. The importance of pressor and depressor factors for hypertension in pregnancy. Scand J Clin Lab Invest Suppl 1984;169:48-56.
23. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-249.
24. Granger JP, Alexander BT, Uinas MT, et al. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 2002;9:147-160.
25. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-1423.
26. Zhou Y, Bellingard V, Feng KT, et al. Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PIGF, and VEGF-C. Dev Biol 2003;263:114-125.
27. Ahmed A, Perkins J. Angiogenesis and intrauterine growth restriction. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:981-998.
28. Charnock-Jones DS, Burton GJ. Placental vascular morphogenesis. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:953-968.
29. Ong S, Lash G, Baker PN. Angiogenesis and placental growth in normal and compromised pregnancies. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:969-980.
30. Torry DS, Mukherjea D, Arroyo J, et al. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Invest 2003;10:178-188.
31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
32. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343.
33. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-583.
34. Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 2003;286:H153-H164.
35. Hiratsuka S, Maru Y, Okada A, et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001;61:1207-1213.
36. Athanassiades A, Lala PK. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta 1998;19:465-473.
37. Cheung CY. Vascular endothelial growth factor: possible role in fetal development and placental function. J Soc Gynecol Invest 1997;4:169-177.
38. Clark DE, Smith SK, He Y, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998;59:1540-1548.
39. Desai J, Holt-Shore V, Tony RJ, et al. Signal transduction and biological function of placenta growth factor in primary human trophoblast. Biol Reprod 1999;60:887-892.
40. Hayman R, Brockelsby J, Kenny L, et al. Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor. J Soc Gynecol Invest 1999;6:3-10.
41. Hornig C, Barleon B, Ahmad S, et al. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000;80:443-454.
42. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-328.
43. Kupferminc MJ, Daniel Y, Englender T, et al. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 1997;38:302-306.
44. Lash GE, Cartwright JE, Whitley GS, et al. The effects of angiogenic growth factors on extravillous trophoblast invasion and motility. Placenta 1999;20:661-667.
45. Lyall F, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod 1996;1:107-116.
46. Lyall F, Greer IA, Boswell F, et al. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1997;104:223-228.
47. Reuvekamp A, Velsing-Aarts FV, Poulina IE, et al. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999;106:1019-1022.
48. Reynolds LP, Redmer DA. Utero-placental vascular development and placental function. J Anim Sci 1995;73:1839-1851.
49. Schlembach D, Beinder E. Angiogenic factors in preeclampsia. J Soc Gynecol Invest 2003;10:316A.
50. Taylor RN, de Groot CJ, Cho YK, et al. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:17-31.
51. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-182.
52. Tidwell SC, Ho HN, Chiu WH, et al. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001;184:1267-1272.
53. Torry DS, Wang HS, Wang TH, et al. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179:1539-1544.
54. Torry DS, Ahn H, Barnes EL, et al. Placenta growth factor: potential role in pregnancy. Am J Reprod Immunol 1999;41:79-85.
55. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-5563.
56. Vuorela P, Hatva E, Lymboussaki A, et al. Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 1997;56:489-494.
57. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.
58. Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348-2351.
59. Chaiworapongsa T, Romera R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-47.
60. Livingston JC, Chin R, Haddad B, et al. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000;183:1554-1557.
61. Kincaid-Smith P. The renal lesion of preeclampsia revisited. Am J Kidney Dis 1991;17:144-148.
62. Hill PA, Fairley KF, Kincaid-Smith P, et al. Morphologic changes in the renal glomerulus and the juxtaglomerular apparatus in human preeclampsia. J Pathol 1988;156:291-303.
63. Gaber LW, Spargo BH, Lindheimer MD. Renal pathology in pre-eclampsia. Baillieres Clin Obstet Gynaecol 1987;1:971-995.
64. Strevens H, Wide-Swensson D, Hansen A, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 2003;110:831-836.
65. Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1997;177:1003-1010.
66. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.
67. Gant NF, Chand S, Whalley PJ, et al. The nature of pressor responsiveness to angiotensin II in human pregnancy. Obstet Gynecol 1974;43:854.
68. Gant NF, Chand S, Worley RJ, et al. A clinical test useful for predicting the development of acute hypertension in pregnancy. Am J Obstet Gynecol 1974;120:1-7.
69. Harrington KF, Campbell S, Bewley S, et al. Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. Eur J Obstet Gynecol Reprod Biol 1991;42 Suppl:S14-S20.
70. Kurmanavicius J, Florio I, Wisser J, et al. Reference resistance indices of the umbilical, fetal middle cerebral and uterine arteries at 24-42 weeks of gestation. Ultrasound Obstet Gynecol 1997;10:112-120.
71. Bower S, Schuchter K, Campbell S. Doppler ultrasound screening as part of routine antenatal scanning: prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1993;100:989-994.
72. Adamson SL, Morrow RJ, Bascom PA, et al. Effect of placental resistance, arterial diameter, and blood pressure on the uterine arterial velocity waveform: a computer modeling approach. Ultrasound Med Biol 1989;15:437-442.
73. Ochi H, Suginami H, Matsubara K, et al. Micro-bead embolization of uterine spiral arteries and changes in uterine arterial flow velocity waveforms in the pregnant ewe. Ultrasound Obstet Gynecol 1995;6:272-276.
74. Ochi H, Matsubara K, Kusanagi Y, et al. Significance of a diastolic notch in the uterine artery flow velocity waveform induced by uterine embolisation in the pregnant ewe. Br J Obstet Gynaecol 1998;105:1118-1121.
75. Talbert DG. Uterine flow velocity waveform shape as an indicator of maternal and placental development failure mechanisms: a model-based synthesizing approach. Ultrasound Obstet Gynecol 1995;6:261-271.
76. Lin S, Shimizu I, Suehara N, et al. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995;85:760-765.
77. Olofsson P, Laurini RN, Marsal K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol 1993;49:161-168.
78. Campbell S, Black RS, Lees CC, et al. Doppler ultrasound of the maternal uterine arteries: disappearance of abnormal waveforms and relation to birthweight and pregnancy outcome. Acta Obstet Gynecol Scand 2000;79:631-634.
79. Albaiges G, Missfelder-Lobos H, Lees C, et al. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2000;96:559-564.
80. Chappell L, Bewley S. Pre-eclamptic toxaemia: the role of uterine artery Doppler. Br J Obstet Gynaecol 1998;105:379-382.
81. Zimmermann P, Eirio V, Koskinen J, et al. Doppler assessment of the uterine and uteroplacental circulation in the second trimester in pregnancies at high risk for pre-eclampsia and/or intrauterine growth retardation: comparison and correlation between different Doppler parameters. Ultrasound Obstet Gynecol 1997;9:330-338.
82. Todros T, Ferrazzi E, Arduini D, et al. Performance of Doppler ultrasonography as a screening test in low risk pregnancies: results of a multicentric study. J Ultrasound Med 1995;14:343-348.
83. North RA, Ferrier C, Long D, et al. Uterine artery Doppler flow velocity waveforms in the second trimester for the prediction of preeclampsia and fetal growth retardation. Obstet Gynecol 1994;83:378-386.
84. Schulman H. The clinical implications of Doppler ultrasound analysis of the uterine and umbilical arteries. Am J Obstet Gynecol 1987;156:889-893.
85. Fleischer A, Schulman H, Farmakides G, et al. Uterine artery Doppler velocimetry in pregnant women with hypertension. Am J Obstet Gynecol 1986;154:806-813.
86. Papageorghiou AT, Yu CK, Bindra R, et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:441-449.
87. Ahmed A, Li XF, Dunk C, et al. Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors 1995;12:235-243.
88. Charnock-Jones DS, Sharkey AM, Boocock CA, et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod 1994;51:524-530.
89. Clark DE, Smith SK, Sharkey AM, et al. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 1996;11:1090-1098.
90. Khaliq A, Dunk C, Jiang J, et al. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction upregulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab Invest 1999;79:151-170.
91. Lash GE, Taylor CM, Trew AJ, et al. Vascular endothelial growth factor and placental growth factor release in cultured trophoblast cells under different oxygen tensions. Growth Factors 2002;20:189-196.
92. Shore VH, Wang TH, Wang CL, et al. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997;18:657-665.
93. Helske S, Vuorela P, Carpen O, et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001;7:205-210.
94. Kumazaki K, Nakayama M, Suehara N, et al. Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathologic conditions. Hum Pathol 2002;33:1069-1077.
95. Trollmann R, Amann K, Schoof E, et al. Hypoxia activates the human placental vascular endothelial growth factor system in vitro and in vivo: up-regulation of vascular endothelial growth factor in clinically relevant hypoxic ischemia in birth asphyxia. Am J Obstet Gynecol 2003;188:517-523.
96. Ahmed A, Dunk C, Kniss D, et al. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest 1997;76:779-791.
97. Athanassiades A, Hamilton GS, LaIa PK. Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillous trophoblast. Biol Reprod 1998;59:643-654.
98. Benirschke K, Kaufmann P. Pathology of the human placenta. 4th ed. New York: Springer; 2000. pp 116-154.
99. Kingdom JC, Kaufmann P. Oxygen and placental vascular development. Adv Exp Med Biol 1999;474:259-275.
100. Todros T, Sciarrone A, Piccoli E, et al. Umbilical Doppler waveforms and placental villous angiogenesis in pregnancies complicated by fetal growth restriction. Obstet Gynecol 1999;93:499-503.
101. Kingdom J, Huppertz B, Seaward G, et al. Development of the placental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol 2000;92:35-43.
102. Geva E, Ginzinger DG, Zaloudek CJ, et al. Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 2002;87:4213-4224.
103. Mayhew TM. Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. Placenta 2002;23:742-750.
104. Kaufmann P, Luckhardt M, Schweikhart G, et al. Cross-sectional features and three-dimensional structure of human placental villi. Placenta 1987;8:235-247.
105. Jackson MR, Walsh AJ, Morrow RJ, et al. Reduced placental villous tree elaboration in small-for-gestational-age pregnancies: relationship with umbilical artery Doppler waveforms. Am J Obstet Gynecol 1995;172:518-525.
106. Krebs C, Macara LM, Leiser R, et al. Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Am J Obstet Gynecol 1996;175:1534-1542.
107. Boyle JW, Lotgering FK, Longo LD. Acute embolization of the uteroplacental circulation: uterine blood flow and placental CO diffusing capacity. J Dev Physiol 1984;6:377-386.
108. Brar HS, Medearis AL, DeVore GR, et al. A comparative study of fetal umbilical velocimetry with continuous- and pulsed-wave Doppler ultrasonography in high-risk pregnancies: relationship to outcome. Am J Obstet Gynecol 1989;160:375-378.
109. Trudinger BJ, Cook CM. Doppler umbilical and uterine flow waveforms in severe pregnancy hypertension. Br J Obstet Gynaecol 1990;97:142-148.
110. Trudinger BJ, Cook CM, Giles WB, et al. Fetal umbilical artery velocity waveforms and subsequent neonatal outcome. Br J Obstet Gynaecol 1991;98:378-384.
111. Kuzuya M, Ramos MA, Kanda S, et al. VEGF protects against oxidized LDL toxicity to endothelial cells by an intracellular glutathione-dependent mechanism through the KDR receptor. Arterioscler Thromb Vasc Biol 2001;21:765-770.
112. Horowitz JR, Rivard A, van der ZR, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997;17:2793-2800.
113. Polliotti BM, Fry AG, Sailer DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-1274.
114. Su YN, Lee CN, Cheng WF, et al. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001;97:898-904.
115. Tjoa ML, van Vugt JM, Mulders MA, et al. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001;98:600-607.
116. Yang S, Toy K, Ingle G, et al. Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 2002;22:1797-1803.
117. Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998;252:743-746.
118. Kroll J, Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun 1999;265:636-639.
119. Tsurumi Y, Murohara T, Krasinski K, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997;3:879-886.
120. He H, Venema VJ, Gu X, et al. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999;274:25130-25135.
121. +. Biochem J 2001;353:503-512.
122. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-12608.
123. Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999;104:913-923.
124. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
125. Bayhan G, Atamer Y, Atamer A, et al. Significance of changes in lipid peroxides and amioxidant enzyme activities in pregnant women with preeclampsia and eclampsia. Clin Exp Obstet Gynecol 2000;27:142-146.
126. Mutlu-Turkoglu U, Aykac-Toker G, Ibrahimoglu L, et al. Plasma nitric oxide metabolites and lipid peroxide levels in preeclamptic pregnant women before and after delivery. Gynecol Obstet Invest 1999;48:247-250.
127. Winkler K, Wetzka B, Hoffmann MM, et al. Triglyceride-rich lipoproteins are associated with hypertension in pre-eclampsia. J Clin Endocrinol Metab 2003;88:1162-1166.
128. Takacs P, Kauma SW, Sholley MM, et al. Increased circulating lipid peroxides in severe preeclampsia activate NF-kappaB and upregulate ICAM-1 in vascular endothelial cells. FASEB J 2001;15:279-281.
129. Hubel CA. Oxidative stress in the pathogenesis of pre-eclampsia. Proc Soc Exp Biol Med 1999;222:222-235.
130. Vaughan JE, Walsh SW. Oxidative stress reproduces placental abnormalities of preeclampsia. Hypertens Pregnancy 2002;21:205-223.
131. Myatt L, Kossenjans W, Sahay R, et al. Oxidative stress causes vascular dysfunction in the placenta. J Matern Fetal Med 2000;9:79-82.
132. Walsh SW, Vaughan JE, Wang Y, et al. Placental isoprostane is significantly increased in preeclampsia. FASEB J 2000;14:1289-1296.
133. Roes EM, Raijmakers MT, Zusterzeel PL, et al. Deficient detoxifying capacity in the pathophysiology of preeclampsia. Med Hypotheses 2000;55:415-418.
134. Sagol S, Ozkinay E, Ozsener S. Impaired antioxidant activity in women with pre-eclampsia. Int J Gynaecol Obstet 1999;64:121-127.
135. Kharb S. Total free radical trapping antioxidant potential in pre-eclampsia. Int J Gynaecol Obstet 2000;69:23-26.
136. Chappell LC, Seed PT, Briley A, et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002;187:127-136.
137. Gratacos E, Casals E, Gomez O, et al. Increased susceptibility to low density lipoprotein oxidation in women with a history of pre-eclampsia. BJOG 2003;110:400-404.
138. Ozan H, Ilcol Y, Kimya Y, et al. Plasma anti-oxidant status and lipid profile in non-gravida women with a history of pre-eclampsia. J Obstet Gynaecol Res 2002;28:274-279.
139. De Bandt M, Ben Mahdi MH, Ollivier V, et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 2003;171:4853-4859.